SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
furnished a corporate slide presentation (the June 15
Presentation) providing additional data from the Companys
ongoing, open-label Phase 2 company-sponsored trial, which is
assessing the safety, tolerability, pharmacokinetic and
pharmacodynamics of SEL-212 in patients with elevated uric acid
levels and symptomatic gout (the Phase 2 Trial).
(the Updated Presentation), which is attached to this Current
Report on Form 8-K as Exhibit 99.1. In addition to incorporating
information from the June 15 Presentation, the Updated
Presentation includes, among other things, data with respect to
Cohort 7 of the Phase 2 Trial, which were not contained in the
June 15 Presentation.
amend the materials attached hereto as Exhibit 99.1.
99.1 attached hereto, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
enrolled in the Phase 2 Trial as of June 12, 2017 from 60 to 62
and (ii) the percentage of patients reporting a gout flare in the
first month of treatment from 15% to 14% as a result of the
increase in the number of patients.
Corporate presentation of Selecta Biosciences, Inc.
dated June 21, 2017
SELECTA BIOSCIENCES INC ExhibitEX-99.1 2 a991_selectainvestorpres.htm EXHIBIT 99.1 a991_selectainvestorpres June 21,…To view the full exhibit click
here About SELECTA BIOSCIENCES, INC. (NASDAQ:SELB)
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The Company’s product candidates are in development. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s technology allows for the design of SVP therapies that can stimulate immune responses against a range of relevant antigens. Its initial immune-stimulating product candidate is a synthetic vaccine against nicotine for the market of smoking cessation and relapse prevention.